Med spa marketing for multi-location aesthetics chains and platforms

Nobody at a multi-clinic aesthetics operator is short of leads. The forms come in, the click-to-call volume is fine, and the monthly report shows cost per lead moving in the right direction. Revenue does not follow, and the report has no line on it that explains why.

The number that explains it is lead to sold — the share of inquiries that end as a paid treatment or a signed package — and it is not a marketing metric in the way most agencies use the word. It is decided by how fast the lead was called, by whether the consult was booked into a slot the patient could actually take, by whether the consultant asked for the sale, and by whether the payment plan was offered before the patient left the room. Every one of those happens after the click.

So that is where we instrument first. In this business the media is rarely the constraint, and an agency reporting cost per lead without lead-to-sold beside it is reporting the half of the funnel it controls.

Cost per lead is down and revenue per clinic is flat. Two clinics forty miles apart, same brand, same offer, same pricing — one converts at nearly twice the rate of the other, and the spread between clinics is the thing nobody has been able to explain. The consultants who close are the ones who came in with sales experience, and there is no system that transfers what they do to the ones who did not. Laser hair removal packages sold two years ago are running out and nothing was built to convert those patients into anything else. Memberships are sold hard and churn quietly. The last three agencies all opened with the same social-first pitch and none of them asked to see the schedule.

Underneath all of it is a single complaint, phrased differently every time: nobody can tell the operator which of the four businesses inside the clinic is actually making money this month.

The American Med Spa Association's 2024 State of the Industry report, on 2023 data, puts 81% of the market in a single location, roughly 3% under private-equity ownership, and multi-location operators averaging around nine sites. That distribution is why almost everything published about med spa marketing is useless to you: it is written for the owner-operator with one room, one injector and a Facebook page.

A platform running dozens or hundreds of clinics has none of that operator's problems and all of a different set. Consistency across clinics, not creativity. Consultant performance as a managed variable, not a personality. Capacity as inventory, because a treatment room that sits idle at eleven on a Tuesday is a loss that cannot be recovered. Pricing and promotion governed centrally while the demand is intensely local.

We do not serve the single room. That is not a slight — it is a different business, and it is well served elsewhere. This page is for the operator whose problem is that a hundred clinics do not behave alike.

Four service lines, four different economics, and most reporting in this category runs them on one blended cost per lead — which is the reason the last report was useless.

Laser hair removal is a package sold once, at a high ticket, usually against a payment plan, to a patient who may never buy anything else. Injectables are a repeat cycle measured in weeks, where the entire value of the patient is in the second, sixth and twentieth appointment and almost none of it is in the first. Body contouring is a single high-ticket close after a longer consideration period, with a consult-to-treatment rate that is the whole business. Membership is a retention business wearing an acquisition costume — the number that matters is churn, not sign-ups.

Blend those four and every one of them is mispriced. The injectable line looks expensive because it is charged the full acquisition cost of a patient it will keep for years. The package line looks cheap because it is charged nothing for the fact that the patient does not come back.

We report them separately from day one, per clinic.

The elective work downstream of GLP-1 weight loss is the more interesting half of this story and it is the half almost nobody is writing about. Patients who lost substantial weight on a GLP-1 arrive with loose skin, changed proportions and facial volume loss — and they arrive as exactly the patient this industry is built to serve: motivated, cash-paying, choosing for themselves, and already comfortable with a clinical setting.

This is not a forecast. Sono Bello, at 141 centres, publishes a procedure named verbatim “Post GLP-1 Weight Loss Support” — body contouring and excess-skin removal for patients who lost the weight somewhere else — and does not prescribe GLP-1 at all. The largest operator in the category has already productised the downstream and skipped the drug.

The strategic point is the direction of the dependency. This demand grows as GLP-1 use grows, and it is insulated from everything that makes the prescribing side fragile — supply, compounding rules, manufacturer pricing, payer coverage. It is elective, cash-pay, patient-chosen, high-ticket work with a long consideration period, which means it rewards exactly the instrumentation this page describes: consult-to-treatment conversion, follow-up that survives a patient thinking about it for two months, and financing offered before the patient leaves.

If you build one thing against GLP-1, build this one.

Medical weight management can be a good line inside an aesthetics platform. It is not the growth engine it was two years ago, and the reason is a matter of public record rather than opinion.

The economics that made compounded semaglutide attractive depended on a shortage. On 21 February 2025 the FDA declared the semaglutide shortage resolved, which removed the statutory basis for 503B outsourcing facilities to compound what is essentially a copy of an approved drug. The margin that came with compounding largely went with it. At the same time the manufacturers began selling direct to patients — NovoCare and LillyDirect both publish self-pay pricing — so a clinic charging a retail markup on a branded drug is now quoting against the manufacturer's own price list, in public.

There is also a demand-classification problem worth naming: a large share of GLP-1 users report insurance coverage, which makes this line partly payer-gated. Payer-gated demand behaves nothing like the rest of your book, and it does not respond to the same instruments.

None of that means drop the line. It means run it as a service with a defensible margin and a clear role — often as an entry point into work that does not have a cliff — and it means refusing to build a growth plan on top of it. An agency that pitches you GLP-1 as the category's growth story in 2026 has not read the filings.

Platforms in this category grow by opening, not only by buying, and the new-clinic ramp is the most predictable number in the business and the least instrumented. Every operator has an internal view of how long a new site takes to reach maturity. Very few can say what actually drives the variance between one that got there early and one that never did.

The pre-open window is where most of it is decided: whether the location was listed and ranking before the doors opened, whether there was a bookable schedule at launch, whether the first month's inquiries were answered by somebody whose job it was, and whether the local offer was distinguishable from the offer at every other clinic in the network. Demand mapping for the catchment belongs in that window too, before the lease is signed rather than after the first flat quarter.

We build the ramp as a measured sequence with a target curve per site, and we report a new clinic against that curve rather than against the mature ones. A site that is behind at week six is recoverable. A site that is behind at month nine is usually being staffed for a demand level it was never given.